Zions Bancorporation Has $207,000 Stake in Aetna Inc (AET)
Zions Bancorporation increased its stake in Aetna Inc (NYSE:AET) by 495.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,303 shares of the company’s stock after acquiring an additional 1,084 shares during the period. Zions Bancorporation’s holdings in Aetna were worth $207,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bruderman Asset Management LLC purchased a new position in Aetna in the second quarter valued at $106,000. Lloyds Banking Group plc purchased a new position in Aetna in the third quarter valued at $106,000. Moisand Fitzgerald Tamayo LLC purchased a new position in Aetna in the third quarter valued at $116,000. Westside Investment Management Inc. increased its holdings in Aetna by 53.5% in the second quarter. Westside Investment Management Inc. now owns 1,148 shares of the company’s stock valued at $177,000 after buying an additional 400 shares during the last quarter. Finally, Phocas Financial Corp. purchased a new position in Aetna in the second quarter valued at $182,000. Institutional investors and hedge funds own 88.01% of the company’s stock.
Aetna Inc (NYSE:AET) opened at $181.33 on Wednesday. The stock has a market capitalization of $59,223.11, a PE ratio of 17.78, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. Aetna Inc has a twelve month low of $116.04 and a twelve month high of $192.37. The company has a current ratio of 0.53, a quick ratio of 0.53 and a debt-to-equity ratio of 0.52.
Aetna (NYSE:AET) last released its quarterly earnings results on Tuesday, October 31st. The company reported $2.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.39. Aetna had a return on equity of 21.84% and a net margin of 2.93%. The firm had revenue of $14.99 billion for the quarter, compared to analyst estimates of $15.12 billion. During the same quarter last year, the company posted $2.07 earnings per share. The business’s revenue was down 5.0% on a year-over-year basis. sell-side analysts forecast that Aetna Inc will post 9.78 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Thursday, January 11th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date is Wednesday, January 10th. Aetna’s dividend payout ratio is currently 37.04%.
In related news, President Karen S. Lynch sold 15,271 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $161.91, for a total transaction of $2,472,527.61. Following the transaction, the president now owns 64,261 shares of the company’s stock, valued at $10,404,498.51. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Margaret M. Mccarthy sold 10,288 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $162.85, for a total value of $1,675,400.80. Following the transaction, the executive vice president now directly owns 33,563 shares in the company, valued at approximately $5,465,734.55. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.
Several equities analysts recently commented on AET shares. Piper Jaffray Companies reissued a “hold” rating and issued a $187.00 target price on shares of Aetna in a report on Friday, November 3rd. Zacks Investment Research lowered Aetna from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Argus lowered Aetna from a “buy” rating to a “hold” rating and set a $185.00 target price on the stock. in a report on Wednesday, December 6th. BMO Capital Markets increased their target price on Aetna from $175.00 to $200.00 and gave the company a “market perform” rating in a report on Friday, October 27th. Finally, Cantor Fitzgerald lowered Aetna from an “overweight” rating to a “neutral” rating in a report on Thursday, October 26th. Twelve research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Aetna presently has an average rating of “Buy” and an average price target of $175.19.
TRADEMARK VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/zions-bancorporation-has-207000-stake-in-aetna-inc-aet/1760870.html.
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc (NYSE:AET).
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with Analyst Ratings Network's FREE daily email newsletter.